Sequencing of treatments for advanced kidney cancer remains uncertain

There are now a number of licensed drug options available for the treatment of advanced renal cell carcinoma (RCC). Many of them have data supporting their use as first- and second-line treatments. However, it is still not clear what sequence these drugs should be used in, especially as data coming out of clinical trials may […]

read more

Adjuvant therapy for renal cell carcinoma

The following article is a good review of the data from recent clinical trials of adjuvant targeted therapy for renal cell carcinoma (RCC). Adjuvant therapy is the treatment received after surgery to prevent the cancer from spreading and/or returning. The success of targeted therapies, such as vascular endothelial growth factor (VEGF) inhibitors (sunitinib and pazopanib) […]

read more

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

Fantastic news for people with advanced kidney cancer: the lenvatinib (Kisplyx) plus everolimus (Afinitor) combination has been recommended by the National Institute for Health and Care Excellence (NICE) for use by the NHS in England and Wales for people with advanced renal cell carcinoma (RCC) that has been previously treated. This is the first combination of treatments to be […]

read more

The evolving management of advanced renal cell carcinoma

This article, published in UroToday this week, is a nice summary of the latest treatments available or in development for clear cell renal cell carcinoma and non-clear cell renal cell carcinoma. Read the article in UroToday here

read more

Initiation of phase 2 clinical trial of glutaminase inhibitor plus everolimus for renal cell carcinoma

Calithera Biosciences, an American pharmaceutical company focused on developing drugs for the treatment of cancer, has announced the initiation of a randomised phase 2 clinical trial of CB-839, a glutaminase inhibitor, combined with everolimus (Afinitor)‎ in patients with clear cell renal cell carcinoma (RCC). Many cancers are dependent on the nutrient glutamine for growth and […]

read more

FDA grants fast track designation to new glutaminase inhibitor CB-839 for metastatic kidney cancer

Calithera Biosciences announced yesterday that the FDA has granted fast track designation to CB-839 for use in combination with everolimus for the treatment of patients with metastatic renal cell carcinoma (RCC) who received at least two prior courses of treatment. Fast track designation by the FDA expedites the review process to facilitate development of drugs which treat […]

read more

Cabozantinib for advanced kidney cancer rejected for the second time by NICE

Unfortunately, the National Institute for Health and Care Excellence (NICE) have rejected cabozantinib (Cabometyx®) as a second-line treatment for metastatic kidney cancer for the second time. This is despite it’s proven effectiveness at prolonging the overall survival and progression-free survival of previously treated kidney cancer patients compared to everolimus in the METEOR trial. Further to […]

read more

Advances in kidney cancer drug treatments shake up drug choices

The following article provides a comprehensive summary of the changing landscape in the choice of first and second-line drug treatments for advanced kidney cancer, with input from Dr Eric Jonasch, a professor of genitourinary medical oncology at The University of Texas MD Anderson Cancer Center and vice chair of the Kidney Cancer Guidelines Committee for […]

read more

Patient selection is key for kidney cancer treatments

There are now a number of treatment options available for people with advanced kidney cancer as first- or second-line treatments. This article talks about the importance of keeping the patient’s characteristics and goals in mind when oncologists decide which treatment to use. “That gives you an idea of which agent to give to them and, […]

read more
Showing 21 to 30 of 46 results
  TOP